GlassScriptPhysician profile
Amberlee Moore
NPI 1427589191
$3,746.06
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,512 · 2022: $1,757 · 2023: $457 · 2024: $20.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $667.96 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $293.77 | 2021-2023 | Farxiga |
| Amgen INC. | $255.02 | 2021-2023 | Prolia, Evenity, Otezla |
| Novo Nordisk INC | $216.56 | 2021-2023 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $214.17 | 2022 | |
| Radius Health, INC. | $172.83 | 2021-2023 | Tymlos |
| Lilly USA, LLC | $161.21 | 2021-2023 | Trulicity, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $154.05 | 2021-2022 | |
| Pfizer INC. | $120.71 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.15 | 2021-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.77 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $90.61 | 2022-2023 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $84.14 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $77.83 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.68 | 2022-2023 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amberlee Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.